CRL financials
Charles River Laboratories International, Inc. · end-of-day data as of Oct 16, 2026
Charles River Laboratories International, Inc.
$300.15+32.5%
Buy · 18 analystsPT $309.33 +3.1%
CRL reported revenue of $1B for the quarter ended Jun 27, 2026 (Q2 FY2026), down 2.7% from a year earlier. It posted diluted EPS of -$0.03, free cash flow of $149M and a net margin of -0.1%.
Valuation
- P/E—
- P/E vs own—
- P/E vs sector—
- FCF yield+2.6%
- Market cap$14.46B
Quarterly results
Q2 FY2026: Revenue -2.7% year over year, free cash flow 14.8% of revenue, operating margin 11.9%.
RevenueFree cash flow
| Q2 FY2026 | Jun 27, 2026 | $1B | -0.03 | $149M | 36.2% | 11.9% | -0.1% |
| Q1 FY2026 | Mar 28, 2026 | $996M | -0.30 | -$14.83M | 28.0% | 12.0% | -1.5% |
| Q4 FY2025 | Dec 27, 2025 | $994M | -5.62 | $58.57M | 31.0% | 12.1% | -27.8% |
| Q3 FY2025 | Sep 27, 2025 | $1B | 1.10 | $178M | 33.7% | 13.3% | 5.4% |
| Q2 FY2025 | Jun 28, 2025 | $1.03B | 1.06 | $169M | 34.6% | 9.7% | 5.1% |
| Q1 FY2025 | Mar 29, 2025 | $984M | 0.50 | $112M | 32.3% | 7.6% | 2.6% |
| Q4 FY2024 | Dec 31, 2024 | $1B | -4.22 | $83.75M | 28.4% | -16.7% | -21.5% |
| Q3 FY2024 | Sep 28, 2024 | $1.01B | 1.33 | $213M | 34.6% | 11.6% | 6.8% |
| Q2 FY2024 | Jun 29, 2024 | $1.03B | 1.74 | $154M | 34.5% | 14.8% | 8.8% |
| Q1 FY2024 | Mar 30, 2024 | $1.01B | 1.30 | $50.74M | 34.1% | 12.5% | 6.7% |
| Q4 FY2023 | Dec 31, 2023 | $1.01B | 3.62 | $143M | 35.9% | 13.1% | 18.5% |
| Q3 FY2023 | Sep 30, 2023 | $1.03B | 1.69 | $140M | 35.2% | 14.8% | 8.5% |